page

Explore expert perspectives, trends, and innovations <br />
shaping the future of specialty chemicals and your market.

Insights 
from the Industry

Industry Articles


GLP-1 agonists did something no supplement brand planned for: they made weight management a medical conversation, not a lifestyle one.



Ozempic and its cousins didn't just change the patient journey. They changed the consumer brief. Weight management brands are now working in two parallel markets: consumers on a GLP-1 who need complementary support, and consumers deliberately not on one who want ingredients that actually earn the category name.



The common denominator in both markets is the same problem, repackaged: lean mass preservation, visceral fat reduction, metabolic health. A 2024 meta-analysis of 22 GLP-1RA trials found that lean mass loss accounted for approximately 25% of total weight lost on these drugs, with semaglutide 2.4 mg weekly among the least effective at preserving lean mass. Individual trials have reported the lean-mass fraction of total weight loss as high as 40–45%. The scale isn't the point anymore. Body composition is.



That's the ingredient brief for 2026.



Why most weight management ingredients aren't built for it



The category's historical toolkit — glucomannan, green tea extract, Garcinia, chromium — does not answer the body-composition question in a clinically defensible way. Most of this literature is thin, old, or measures the wrong outcome. A 12-week study showing "reduced body weight" against placebo is not the same as a study showing reduced visceral fat over six months with liver safety monitored.



Brand owners formulating for 2026 need ingredients with:




Randomised, placebo-controlled clinical data



Duration long enough to matter (3–6 months)



Body composition endpoints, not just scale weight



Fat mass and fat distribution data, not just BMI



Safety markers, especially liver




Very few weight management ingredients clear all five. Morosil® is one of them.



What the Morosil® data actually says



Morosil® is a standardised extract from a specific cultivar of Sicilian Moro red oranges (Citrus sinensis L. Osbeck), produced by Bionap in the volcanic soils around Mt. Etna. The active phytocomplex is a defined pool of anthocyanins (primarily cyanidin 3-O-glucoside), hydroxycinnamic acids, flavanones and ascorbic acid — standardised batch-to-batch.



The dose is consistent across the published clinical work: 400 mg/day. Two randomised placebo-controlled trials underpin the evidence base.



Cardile et al. 2015 — 12 weeks, Natural Product Research



The first human trial, published in Natural Product Research, supplemented 60 overweight adults with 400 mg/day of Morosil® or placebo for 12 weeks. The active group showed significant reduction in BMI after just 4 weeks, with body weight, BMI, waist circumference and hip circumference all significantly different from placebo by the end of the study (p &lt; 0.05).



Briskey et al. 2022 — 6 months, Nutrients



The 2022 study extended the evidence base to 6 months with an RCT in Nutrients. Overweight but otherwise healthy adults aged 20–65 received 400 mg/day of Morosil® or placebo alongside a calorie-controlled diet and exercise. Results at 6 months, Morosil® vs placebo:




Body mass reduction: 4.2% vs 2.2% (p = 0.015) — roughly 1.9-times greater loss.



BMI: significantly greater reduction (p = 0.019).



Waist circumference: −3.9 cm vs −1.7 cm (p = 0.017).



Hip circumference: −3.4 cm vs −2.0 cm (p = 0.049).



Fat mass: significant reduction (p = 0.012).



Visceral and subcutaneous fat distribution: significantly improved (p = 0.018 and p = 0.006 respectively).



Liver safety: all markers within normal range at 3 and 6 months in both groups.




The mechanism proposed by the authors is regulation of lipid metabolism through fatty acid biosynthesis and oxidation pathways, mediated by the anthocyanin and biophenol pool — not stimulant action, not appetite suppression, not fibre bulking.



A 2025 systematic review of Moro orange extract trials assigned Briskey 2022 a low risk of bias across all GRADE domains, while noting the evidence overall as low to very low certainty given the small number of trials — important context for any brand owner evaluating the literature.



NutraIngredients-USA named Morosil® Weight Management Ingredient of the Year.



Why this maps to the GLP-1-era brief



A weight management ingredient that produces fat-specific body composition improvements — rather than generic scale-weight reduction — is exactly the complementary story a brand owner building GLP-1-adjacent products wants to tell. The Briskey 2022 data demonstrates significant reductions in fat mass, visceral fat and subcutaneous fat alongside waist and hip circumference. For consumers concerned about body composition while on or off a GLP-1, that's the clinical anchor the category has been missing.



Morosil® lands cleanly in both positions.



Formulation notes



Morosil® is a standardised powder extract, suitable for:




Capsules and tablets (most clinical data)



Sticks and sachets



Functional beverages and shots



Gummies




For combination formulations targeting metabolic longevity, pair with AvailOm® High EPA for cardiovascular and inflammation endpoints, or with targeted probiotics for the gut-metabolic axis. High-quality plant protein in the same stack addresses the lean-mass preservation concern that sits alongside fat reduction.



Meet us in Barcelona



Safic-Alcan distributes Morosil® across Europe. The Bionap clinical portfolio, formulation starter formulas, and complementary weight-management ingredients (plant proteins for satiety, peptides for muscle preservation) will be on our stand at Vitafoods Europe 2026.



Vitafoods added Weight Management as a new Innovation Award category this year. It's not a coincidence.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Booth 3B143




Register today for Vitafood and come visit ut at our booth


Vitafood is just around the corner!

Morosil® and the GLP-1 era: why body composition is the new weight management brief


Omega-3 is a solved science and an unsolved product.



The science part is comfortable: EPA and DHA, essential for cardiovascular, cognitive, joint and eye function, backed by decades of clinical literature, recognised by every major regulatory body. Consumers know they need it. Brand owners know they should offer it.



The product part is where the category has been stuck for twenty years.



The formats formulators have been forced to live with



Soft gels



Soft gels work, but they're large, the consumer experience is poor (burps, fishy aftertaste, digestion complaints), and they exclude entire formats — no sticks, no gummies, no combination tablets, no functional beverages. For brands building a daily-ritual product for 2026 consumers, the soft gel is a compromise nobody wants to make.



Conventional omega-3 powders



Conventional omega-3 powders are worse. Most are encapsulated oils or oils absorbed onto carbohydrate carriers. The effective EPA+DHA load is low — often below 30% — and the powders are rarely directly compressible into tablets. You end up with bulky formats, compressibility problems at scale, or oxidation issues on shelf.



Ethyl ester



Ethyl ester — the standard concentrate form — requires emulsification via bile salts and hydrolysis by pancreatic lipases before the body can absorb it. Clinically real; commercially fine. But for a longevity-positioned brand trying to tell a bioavailability story, "requires digestion to work" isn't the headline.



The result: for most of the last decade, omega-3 has been the supplement every brand includes and nobody features.



What AvailOm® actually changed



Evonik's AvailOm® is an omega-3 lysine complex: EPA and DHA as free fatty acids, chemically bound to the essential amino acid L-lysine, producing a solid powder with properties the category hadn't seen before.



The primary bioavailability claim is supported by a first-in-human clinical pharmacokinetic study conducted at Wageningen University (The Netherlands) and published in Prostaglandins, Leukotrienes and Essential Fatty Acids in 2020. Evonik confirms the key specifications in its published product documentation[2]:




50% EPA+DHA as free fatty acids by weight — the highest-load omega-3 powder in its class.



~5× higher bioavailability vs a commercial oil-based ethyl-ester formulation (median AUC ratio 5.04 over 0–12h in fasted healthy adults, n=8)[1].



Directly compressible into tablets — smaller, easier-to-swallow formats with combination ingredients.



Multi-year oxidation resistance — shelf stability that opens up global distribution and combination products[2].



No fishy aftertaste or burps — the consumer experience complaint that drives the category's churn.




It's worth noting the Wageningen study's honest scope: it was an acute pharmacokinetic comparison in a fasted state. Independent reviewers have pointed out that the five-times advantage applies most cleanly to the fasted use case and to individuals with compromised fat digestion (low-fat diet, reduced bile availability, gut inflammation)[3]. That still covers a meaningful share of the longevity-consumer profile — and the free fatty acid form plus the oxidation-resistance and direct-compressibility properties deliver the formulation advantages independent of the bioavailability debate.



For formulators, this removes the trade-off between load, stability, and format. You can build a combination tablet with omega-3, botanicals, vitamins, minerals, probiotics — and stand behind the EPA+DHA content on the label.



Three grades, three briefs



AvailOm® comes as a platform, not a single product:




AvailOm® 50 High EPA — minimum 30% EPA + 15% DHA. EPA is associated with cardiovascular, joint and inflammation endpoints. The healthy-ageing grade — the one to specify for longevity-positioned adult brands.



AvailOm® 50 High DHA — fish-oil-derived, higher DHA concentration. DHA is associated with cognitive function, eye health, and infant development. Pregnancy, maternity, and cognitive-ageing positioning.



AvailOm® 50 High DHA Algae — algae-oil-based, minimum 48% DHA as free fatty acids. Vegan and vegetarian. The grade that makes nutricosmetic and cognitive formulations work for the beauty-from-within category.




All grades are sustainably sourced and cleared for marketing in Europe, the US, and most major markets.



Longevity is mid-life now



The longevity conversation in 2026 is not about ageing. It's about the 40-year-old reading Peter Attia, tracking their ApoB, and formulating their own protocol. These consumers read labels. They compare EPA:DHA ratios. They know what "free fatty acid form" means. They notice when a product avoids the soft gel for good reasons.



AvailOm® is the ingredient that lets a brand answer that consumer seriously.



Pair it with clinically-proven weight management ingredients like Morosil® for a metabolic-longevity positioning, or with the right microbiota stack for a systems-level healthspan brief.



Meet us in Barcelona



Safic-Alcan distributes AvailOm® across Europe. The full three-grade range, plus the complementary portfolio for longevity formulations (carotenoids, DHA, antioxidants, minerals), will be on our stand at Vitafoods Europe 2026.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Booth 3B143




Learn more about our presence









How AvailOm® is solving the omega-3 problem brands have been working around


For years, "vegan collagen" was a workaround.



Brand teams knew it. Formulators definitely knew it. The vitamin C + amino acid + silica stack sold as "vegan collagen support" wasn't collagen — it was the cofactors for the collagen your body already makes. Useful biology. Dishonest label.



The consumer got the joke eventually. Returns went up. Trust went down. And the beauty-from-within category — one of the fastest-growing in nutraceuticals — kept carrying a credibility problem nobody wanted to name.



That's changing, on two fronts at once: the arrival of genuine precision-fermented vegan collagen peptides, and a much richer segmentation inside the marine category itself.



What precision fermentation actually unlocks



Collagen is absent from plants. Its building blocks are not. Modern precision fermentation takes that second fact seriously: recombinant collagen peptides, bioidentical to human Type I, produced by engineered microbes, purified to pharmaceutical-grade standards.



The result is a real ingredient, not a proxy. Neutral sensory profile. Compatible with capsules, gummies, powders, beverages, sticks. Vegan and vegetarian certifiable. No bovine spongiform concerns, no fish allergen, no marine sourcing volatility.



For brand owners, this changes the brief completely:




The label says "collagen" and means it.



The sensory profile doesn't fight the formulation.



The sustainability narrative is defensible without handwaving.



The consumer doesn't need to be educated on why the old "boosters" weren't the real thing.




That last point is where most of the category velocity will come from in 2026–27. Safic-Alcan is actively onboarding precision-fermented suppliers as this tier matures — speak to our Life Sciences team for the current state of play.



The marine range doing most of the real work today



While the vegan recombinant tier develops, the marine category has quietly become far more sophisticated than the "fish collagen peptide" of five years ago. Type I collagen — the dominant structural collagen of human skin, accounting for the majority of the dermal extracellular matrix — is also the dominant form of marine collagen, which explains the category's durability. The Safic-Alcan catalogue carries several distinct grades, each with a different brief:




AQUAPRO® Fish Collagen Type I Tripeptide (JXN Collagen Life Sciences) — a hydrolysed marine peptide derived from fish scales, optimised for nutraceutical applications where low molecular weight and rapid bioavailability matter. The tripeptide form is the shortest structurally meaningful collagen fragment, which has implications for absorption kinetics.



Fish Collagen Peptide Type II (JXN Collagen Life Sciences) — designed for nutraceuticals and dietary supplements with Type II–specific endpoints: joint, skin, bone health, and anti-inflammatory positioning. Type II is the matrix protein of cartilage and is the correct specification for joint-led product briefs.



Collagen HM (Copalis) — a marine polypeptide engineered for sports nutrition and skin rejuvenation. The dual positioning matters: brands building performance + recovery + beauty crossover products (an increasingly common brief) don't need two different collagens.



Collactive® (Copalis) — marine collagen combined with elastin oligopeptides, positioned as an antioxidant for nutraceutical applications. Elastin is the structural partner to collagen in skin, and the combination story is defensible in a way that collagen-only formulations are not.



Fish Collagen Peptide — the standard hydrolysed marine grade for nutraceuticals and dietary supplements, with the broadest clinical literature base for skin, joint, and bone endpoints.




Marine collagen peptides are widely reported to offer approximately 1.5-times higher absorption than land-animal sources, attributed to their smaller average peptide molecular weight. The sustainability narrative — fish by-products, circular-economy sourcing — is equally defensible. Flavour-masking is recommended in neutral matrices; the Life Sciences team supports that work.



Plant-based alternatives for the cosmetic-adjacent side of the category



Some "beauty from within" briefs are really topical-adjacent — ingredients specified for a combined ingestible and cosmetic line, or for brands that want a single botanical signature across the range. For that positioning:




Collagen PhytPowder 300 (Greenphyt) — an antioxidant, radiance promoter, restoring and firming agent designed for masks and body wraps, suitable for water-based formulations.



Carrot Collagen (Hyundai Bioland) — a moisturising agent for skin care applications, positioned as a plant-based alternative to animal collagen.




These are cosmetic-side products rather than ingestible nutraceuticals, but they're worth knowing about if your brief spans both sides of the beauty-from-within architecture.



The complement most brands under-formulate



Beauty from within isn't just collagen. Skin ageing is systemic: oxidative stress, inflammation, omega-3 status, gut health, cognitive markers. The brands winning 2026 are building stacks, not single-ingredient capsules.



DHA — the omega-3 fatty acid associated with cognitive and eye health — also matters for skin barrier function. AvailOm® High DHA Algae is the vegan-compatible format most formulators haven't built in yet: 48% DHA as free fatty acids, algae-based, directly compressible, no fishy profile.



And the gut-skin axis is no longer fringe. The 2026 microbiota stack is becoming central to any nutricosmetic brief that wants to hold up under consumer scrutiny.



Meet us in Barcelona



The full collagen spectrum — marine Type I and Type II, Collactive® marine + elastin, plant-based alternatives — plus the complementary stack (omega-3, probiotics, carotenoids, vitamins) will be on our stand at Vitafoods Europe 2026.



→ 5–7 May 2026 · Fira Barcelona Gran Via · Stand 3B143




Learn more about our presence





Register today for Vitafood and come visit ut at our booth

Why the collagen category is finally growing up


Europe's synthetic rubber landscape has shifted more in the past three years than in the&nbsp;previous&nbsp;decade. Sanctions on Russian feedstocks, a wave of plant closures driven by energy costs, and the arrival of Euro 7&nbsp;tyre&nbsp;abrasion rules have fundamentally changed the supply dynamics for styrene-butadiene rubber (SBR). For compounders, procurement teams, and formulation specialists, the market they navigate today bears little resemblance to the one that existed before 2022. This article examines what has changed, why it matters, and how sourcing strategies need to&nbsp;adapt.&nbsp;



What is SBR, and why does it matter&nbsp;for&nbsp;European industry?&nbsp;



Styrene-butadiene rubber is the world's highest-volume synthetic elastomer.&nbsp;According to S&amp;P Global's Chemical Economics Handbook, SBR is produced by&nbsp;copolymerising&nbsp;butadiene and styrene at&nbsp;roughly a&nbsp;3:1 ratio. Two main process families exist:&nbsp;emulsion SBR (E-SBR), which still dominates installed global capacity, and&nbsp;solution SBR (S-SBR), where&nbsp;virtually all&nbsp;new investment is being directed. S-SBR's narrower molecular weight distribution and&nbsp;functionalisation&nbsp;potential make it the polymer of choice for low-rolling-resistance&nbsp;tyre&nbsp;treads — a performance parameter that is now regulated under EU&nbsp;tyre&nbsp;labelling rules.&nbsp;



The end-use split is lopsided:&nbsp;tyres accounted for approximately 68.72% of SBR demand in 2025, with the&nbsp;remainder&nbsp;split across footwear outsoles, adhesives, conveyor belts, technical&nbsp;moulded&nbsp;goods, and polymer-modified bitumen for road construction. Europe's consumption is driven overwhelmingly by its&nbsp;tyre&nbsp;manufacturing industry, concentrated in Germany, France, and Italy — and that demand is shifting structurally toward solution grades.&nbsp;



For the fundamentals of rubber reinforcement that sit alongside SBR in every&nbsp;tyre&nbsp;formulation,&nbsp;Safic-Alcan's article&nbsp;Decoding Carbon Black and Its Crucial Role in the Rubber Industry&nbsp;covers the companion&nbsp;filler&nbsp;chemistry in depth.&nbsp;



The E-SBR / S-SBR distinction: why it matters for sourcing&nbsp;



Understanding the difference between emulsion and solution SBR is a prerequisite for any serious sourcing conversation in Europe today.&nbsp;



E-SBR&nbsp;is produced by&nbsp;polymerising&nbsp;styrene and butadiene monomers in a water-based emulsion at low or high&nbsp;temperature. It is a cost-effective, broadly compatible workhorse grade — the standard choice for passenger and truck&nbsp;tyre&nbsp;carcass compounds, conveyor belts, footwear soles, and general mechanical goods.&nbsp;E-SBR still represented approximately 70.42% of global SBR market volume in 2025, and the large majority of European SBR production capacity is emulsion-based. It is also the grade most affected by the supply-side disruptions discussed below.&nbsp;



S-SBR&nbsp;is produced via anionic solution&nbsp;polymerisation, typically using an organolithium initiator in a hydrocarbon solvent. The process allows precise control over molecular architecture — vinyl content, styrene distribution, molecular weight — and enables end-group&nbsp;functionalisation&nbsp;that improves filler interaction with silica.&nbsp;From 2019 to 2024, demand for E-SBR declined while S-SBR demand surged, highlighting a significant market shift toward grades that meet the stringent specifications of high-performance tyres. S-SBR commands a significant price premium over commodity E-SBR, and capacity additions have been concentrated in this segment.&nbsp;



The practical sourcing implication: the European market faces a two-speed reality. E-SBR is tight due to capacity reductions (see below). S-SBR demand is growing fast but a meaningful&nbsp;portion&nbsp;of high-performance supply still originates from Asia, particularly South Korea and Singapore, with the attendant&nbsp;logistics, lead-time, and emerging carbon-border adjustment risks.&nbsp;



Structural capacity contraction in European SBR production&nbsp;





Europe's synthetic rubber production base has contracted materially since 2021, for reasons that are structural rather than cyclical.



The energy cost problem&nbsp;



Europe's chemical industry entered a deep competitiveness crisis after 2021, when energy costs — natural gas in particular — rose dramatically following Russia's invasion of Ukraine. Synthetic rubber production is energy-intensive: utilities&nbsp;represent&nbsp;a major share of operating costs, particularly for emulsion&nbsp;polymerisation, which requires continuous temperature control and steam.&nbsp;Cefic, the European chemical industry council, estimated that 5% of Europe's total chemical production capacity was shut down in 2023 alone because it was uncompetitive, with more closures following in 2024 and 2025.&nbsp;



Within the polymer and elastomer sector,&nbsp;announced capacity closures in Europe accelerated from 2.9 million tonnes in 2022 to 17.2 million tonnes by 2025&nbsp;across the broader chemicals landscape, with polymers accounting for a significant share.&nbsp;In half of the cases, companies cited energy cost competitiveness as the primary rationale for closing. For E-SBR specifically, European production economics became structurally uncompetitive compared to Asian producers&nbsp;operating&nbsp;with cheaper feedstocks and energy, and against Chinese producers adding capacity at scale.&nbsp;



The consequences for European SBR supply are concrete: a French SBR production site with a capacity of approximately 140,000&nbsp;tonnes/year was announced for permanent closure by 2027, citing sustained losses and adverse European market conditions — leaving France without domestic SBR production for the first time in decades. Capacity reductions have also occurred in Central Europe, where one major E-SBR production line was permanently idled due to unsustainable utility costs. European synthetic rubber production, which previously&nbsp;benefited&nbsp;from geographic proximity to the continent's large&nbsp;tyre&nbsp;manufacturing base, is now a smaller, more concentrated, and more premium-oriented industry than it was five years ago.&nbsp;



The Russia sanctions shock&nbsp;



The second structural disruption is the permanent removal of Russian SBR from the European supply pool. Russia was historically one of the largest exporters of emulsion SBR to European&nbsp;tyre&nbsp;plants, supplying a meaningful share of the continent's commodity E-SBR requirements at competitive prices.&nbsp;



In February 2023,&nbsp;the EU's tenth sanctions package introduced import quotas on Russian synthetic rubber and carbon black, with a full import prohibition taking effect on 1 July 2024. The original quotas were set at 562,973&nbsp;tonnes&nbsp;for synthetic rubber and 752,475&nbsp;tonnes&nbsp;for carbon black — calibrated to pre-war import levels, which gives a clear sense of how significant this supply source had been. Beyond the direct prohibition,&nbsp;the European Commission established a monthly monitoring mechanism on inflows, and successive sanctions packages have continued to close circumvention routes, with the 19th package in force from October 2025 adding further rubber articles to the restricted list.&nbsp;



For procurement teams, the practical implication is harder&nbsp;due&nbsp;diligence on origin declarations — particularly for material routed through third countries where repackaging and re-certification risk is real. The import prohibition covers CN code 4002 synthetic rubber; compliance teams should ensure traceability documentation reflects actual origin, not just the country of last shipment.&nbsp;



The regulatory overlay reshaping SBR demand&nbsp;



Three regulatory forces are now actively influencing both the volume and grade mix of SBR purchased in Europe.&nbsp;



Euro 7&nbsp;tyre&nbsp;abrasion limits&nbsp;



Adopted in 2024, Euro 7 is the first EU regulation to set particle emission limits for&nbsp;tyre&nbsp;wear — a measure that directly affects the chemistry of&nbsp;tyre&nbsp;tread compounds and, by extension, the specification of SBR.&nbsp;Compliance becomes mandatory for all new M1/N1 vehicle type approvals from 29 November 2026, and for all new M1/N1 vehicles placed on the EU market from 29 November 2027. For&nbsp;tyres&nbsp;specifically,&nbsp;the type-approval requirement for C1 passenger car tyres applies from 1 July 2028, with non-compliant tyres banned from the market from 1 July 2030.&nbsp;



Specific abrasion limits are being&nbsp;finalised&nbsp;at UNECE level, with&nbsp;the Euro 7 Regulation leaving it to UN WP.29 to develop limits by June 2026 for passenger car tyres, March 2028 for light commercial vehicles, and March 2030 for heavier vehicles. If UNECE misses those deadlines, the European Commission is empowered to set EU-level limits unilaterally.&nbsp;



For SBR sourcing, this is a clear and durable demand signal: abrasion performance is now a regulatory compliance parameter, not just a marketing one.&nbsp;Functionalised&nbsp;solution SBR grades — engineered to&nbsp;maximise&nbsp;silica coupling efficiency and&nbsp;optimise&nbsp;the rolling resistance / wet grip / wear resistance triangle — are the route to compliant&nbsp;tyre&nbsp;tread compounds.&nbsp;Tyre&nbsp;manufacturers and their compound suppliers are qualifying these grades now, ahead of mandatory deadlines. Buyers who rely&nbsp;predominantly on&nbsp;commodity E-SBR for&nbsp;tyre&nbsp;applications should be modelling the grade migration their compounds will require over the coming years.&nbsp;



The EU&nbsp;tyre&nbsp;labelling regulation&nbsp;



The EU&nbsp;tyre&nbsp;labelling regulation, which grades&nbsp;tyres&nbsp;on rolling resistance, wet grip, and exterior noise, has been in force since 2012 and was updated in 2021. It directly&nbsp;incentivises&nbsp;the use of&nbsp;functionalised&nbsp;S-SBR by creating consumer and OEM demand for the highest-grade labels — an ongoing structural pull on the SBR grade mix, independent of Euro 7.&nbsp;



CBAM and carbon arbitrage&nbsp;



The EU's Carbon Border Adjustment Mechanism (CBAM) does not yet cover synthetic rubber directly, but its shadow is already influencing sourcing decisions.&nbsp;Buyers looking at Korean or Chinese S-SBR imports as a hedge against European capacity constraints must factor CBAM extension scenarios into their total cost of ownership. As the mechanism extends to more sectors — and as EU carbon pricing applies to domestic production — the landed cost differential between European and Asian SBR will narrow. The direction of travel is clear even without a formal extension: buyers pricing Asian S-SBR against European supply on today's landed cost alone are likely to be modelling a differential that will not hold for the life of a multi-year contract.



Sustainability and the bio-based transition&nbsp;



Sustainability is now an active dimension of SBR procurement, not just a communications exercise. Three trends are reshaping the market:&nbsp;



Bio-based butadiene: The key feedstock for SBR — butadiene — is conventionally derived from petroleum-based steam cracking. Several European producers have announced or are developing processes to produce butadiene from bio-derived ethanol, aiming to offer mass-balance or attributional bio-based SBR to&nbsp;tyre&nbsp;customers. These&nbsp;programmes&nbsp;are primarily driven by&nbsp;tyre&nbsp;manufacturers' Scope 3 targets and by the expectations of automotive OEMs, who are increasingly requiring verified Product Carbon Footprint data for rubber raw materials.&nbsp;



Certified sustainable SBR: ISCC PLUS mass-balance certification is becoming a standard specification for premium&nbsp;tyre&nbsp;compound development. Buyers whose OEM customers have committed to science-based carbon reduction targets by 2030 should treat ISCC PLUS documentation as a buying criterion, not an optional extra. Production sites holding this certification can supply bio-attributed or circular-attributed SBR grades with accompanying carbon footprint data.&nbsp;



Rubber recycling and circular feedstocks: The&nbsp;tyre&nbsp;life cycle creates a closed loop opportunity for recovered carbon black and&nbsp;devulcanised&nbsp;rubber to re-enter compound formulations. 



For a broader view of how sustainability-advantaged raw materials perform against fossil-based references in full rubber compounds,&nbsp;Safic-Alcan's comparative study&nbsp;Driving Sustainability-Advantaged Solutions in Rubber Compounding&nbsp;sets out the formulation framework in detail.&nbsp;



What this means for European buyers: practical sourcing considerations&nbsp;



Pulling the threads together, sourcing SBR in Europe in 2026 involves a set of structural decisions that simply did not exist three years ago.&nbsp;



Domestic supply is tighter and more concentrated.&nbsp;With Russian imports banned, meaningful E-SBR capacity permanently closed in France and reduced in Central Europe, the European production base is smaller, more geographically concentrated in Central and Eastern Europe, and more focused on higher-margin solution grades than it was. Dual-sourcing strategies that previously relied on a Russian or Western European backup line now need to reach into Asia or accept tighter allocation from the remaining European plants. This increases&nbsp;logistics&nbsp;risk, lead times, and compliance overhead.&nbsp;



The grade mix is shifting irreversibly toward S-SBR.&nbsp;Euro 7,&nbsp;tyre&nbsp;labelling, and EV-driven performance specifications are all pulling demand toward&nbsp;functionalised&nbsp;solution grades.&nbsp;S-SBR recorded the highest CAGR at roughly 4.27% through 2031, even as emulsion SBR still represented over 70% of 2025 volumes. For non-tyre&nbsp;applications — footwear, mechanical goods, conveyor belts — E-SBR&nbsp;remains&nbsp;the&nbsp;appropriate workhorse, but tightness in European E-SBR availability is making compound reformulation a more active conversation than it used to be.&nbsp;



Feedstock volatility is structural.&nbsp;Styrene and butadiene monomer costs are directly linked to crude oil and naphtha prices, and European producers do not&nbsp;benefit&nbsp;from the backward-integrated margins that Middle Eastern or Chinese competitors enjoy.&nbsp;Feedstock costs typically represent up to 70% of total SBR manufacturing expenses, leaving European producers structurally exposed to commodity price cycles.&nbsp;Price&nbsp;pass-through clauses and monomer-index-linked contracts are increasingly the norm for buyers seeking margin predictability.&nbsp;



Certification is becoming a specification.&nbsp;ISCC PLUS mass-balance documentation and Product Carbon Footprint data per grade are moving from optional differentiators to standard buying criteria, particularly for automotive OEM platforms with hard 2030 Scope 3 targets. Procurement teams that have not yet built SBR sustainability documentation into their supplier qualification process are behind the curve.&nbsp;



Compounding strategy is a competitive variable.&nbsp;With fewer polymer options on the table at competitive European prices,&nbsp;maximising&nbsp;the performance of each&nbsp;tonne&nbsp;of SBR — through&nbsp;optimised&nbsp;silica/silane systems, bio-based or recovered carbon black,&nbsp;appropriate filler&nbsp;loadings, and incorporation of circular content — is increasingly where margin is made or lost. A distributor with regional compounding laboratory capability and multi-supplier access is, in this environment, a genuinely different proposition than a transactional supply channel.&nbsp;



The bottom line&nbsp;



European SBR sourcing in 2026 is tighter, more regulated, and more complex than the market most buyers learned to navigate a decade ago. Domestic production has contracted permanently: Russian imports have gone and will not return on any realistic planning horizon; energy-cost-driven closures have removed meaningful E-SBR capacity from Western Europe; and the remaining European production base is increasingly oriented toward premium S-SBR for high-performance&nbsp;tyre&nbsp;applications. Asian imports fill gaps at the premium&nbsp;end, but&nbsp;carry CBAM risk and longer lead times. The regulatory clock on Euro 7&nbsp;tyre&nbsp;abrasion limits is ticking, and the grade migration it requires is not a future problem — qualification timelines mean it is a present one.&nbsp;



The compounders who will come through this period best are those treating SBR sourcing, compound specification, and regulatory planning as a single integrated conversation rather than three separate workstreams.&nbsp;


Browse our rubber portfolio, including functionalised solution grades and ISCC PLUS certified options.

Qualifying S-SBR grades ahead of Euro 7?

SBR and Synthetic Rubber Sourcing in Europe 


Out of the roughly 2.4 million tonnes of citric acid produced globally each year, the pharmaceutical industry consumes around 12% — a small share by volume, but one that underpins a disproportionately wide range of drug products. From effervescent analgesics and oral antibiotic syrups to lyophilised biologics and blood collection anticoagulant solutions, citric acid (C₆H₈O₇) is one of the most versatile excipients in modern pharmaceutical formulation.



Its three carboxylic groups and one hydroxyl group give it a combination of properties — acidity, buffering capacity, and metal-ion chelation — that no single-function excipient can match. This article outlines how those properties translate into real pharmaceutical applications, and what formulators need to watch for when designing with citric acid. 









Why Citric Acid Is a Multifunctional Excipient



In pharmaceutical formulation, citric acid is rarely asked to do just one job. As reviewed in Citric Acid: A Multifunctional Pharmaceutical Excipient, its utility comes from a single molecule delivering multiple effects in the same formulation:




pH control pH through its three pKa values of 3.13, 4.76 and 6.40, which allow citric acid and citrate buffer systems to hold pH across most of the range used in oral, topical and parenteral formulations.



Metal-ion chelation, which protects oxidation-sensitive active pharmaceutical ingredients (APIs) from trace metal-catalysed degradation.



Effervescence when combined with carbonate or bicarbonate salts, generating CO₂ to support rapid tablet disintegration.



Taste modification, softening bitter API profiles in paediatric and oral liquid dosage forms.



Process roles in lyophilisation, polymer crosslinking, and co-crystal / co-amorphous formulation strategies.




It is also pharmacopoeially well-established: monographs exist in the United States Pharmacopeia (USP) and the European Pharmacopoeia, and both the monohydrate and anhydrous forms are widely used.







Application 1: pH Control and Buffering in Liquid and Parenteral Drugs



This is the most common pharmaceutical use of citric acid. Most drug solutions — oral syrups, elixirs, injectables — require a controlled pH to keep the API stable, soluble, and bioavailable. A pH shift of even one unit can change an API's ionisation state, its solubility, and in some cases its degradation rate.



Citric acid forms buffer systems with its conjugate bases (monosodium, disodium, and trisodium citrate) that resist pH changes across a useful range for pharmaceutical formulations. This is why it appears in parenteral administration dosage forms, including intramuscular injections, as well as in oral solutions and topical preparations.



For injectable formulations, pharmacopoeial-grade citric acid (meeting USP or EP monograph requirements) is mandatory, and supply documentation must cover elemental impurities per ICH Q3D and nitrosamine risk assessment — a point that has become particularly sensitive since the regulatory tightening around nitrosamine contamination in drug products.







Application 2: Effervescent Tablets and Powders



The citric acid + sodium bicarbonate effervescent couple is one of the oldest and most effective solid dosage technologies. On contact with water, the acid and the carbonate react to release CO₂, which disintegrates the tablet, improves dissolution, and masks unpleasant API taste. Effervescent systems are standard for analgesics, antacids, effervescent multivitamins, and rehydration salts.



A more sophisticated application is gastro-retentive floating tablets: effervescent, buoyant tablets designed to float in gastric fluid and release their API slowly over hours. This technology is particularly useful for drugs with absorption windows limited to the upper gastrointestinal tract, or drugs unstable at intestinal pH. Literature describes this approach applied to verapamil, ciprofloxacin, dipyridamole, lisinopril, and venlafaxine, among others — covering antihypertensives, antibiotics, and antidepressants.



For these applications, the anhydrous form of citric acid is preferred: the monohydrate introduces water that can trigger premature reaction with the bicarbonate during manufacturing and storage, compromising tablet integrity and shelf life.







Application 3: Lyophilisation (Freeze-Drying) of Biologics and Labile APIs



Lyophilisation is a cornerstone process for stabilising biologics, peptides, and other heat-sensitive pharmaceuticals. Citric acid is a common excipient in lyophilised formulations, primarily for pH control both during the freezing stage and upon reconstitution.



The challenge in lyophilisation is that buffer components can crystallise at sub-zero temperatures, creating phase separations where local pH values diverge from the bulk formulation — potentially degrading sensitive actives. Citric acid's behaviour in this context has been extensively studied, including its glass transition behaviour. Anhydrous citric acid has a Tg of 11°C and the monohydrate a Tg of −25°C. These are properties of the pure excipient, not of the finished formulation: cycle design depends on Tg′, the glass transition of the maximally freeze-concentrated solution, which must be determined for the formulation as a whole. The excipient values inform that work rather than replace it. These values are critical when designing freeze-drying cycles and determining appropriate shelf temperatures.



A known formulation challenge: in solid state, citric acid retains its degree of ionisation and can cause sucrose protonation and inversion, which may then react with other formulation components and cause decomposition. Formulators designing lyophilised products with sucrose as cryoprotectant need to account for this interaction.







Application 4: Anticoagulant in Blood Collection and Apheresis



One of the most clinically important pharmaceutical uses of citric acid is not as an excipient but as the active component of anticoagulant solutions for extracorporeal blood processing. Anticoagulant Citrate Dextrose Solution USP (ACD Solution A), for example, contains 0.8% citric acid monohydrate, 2.2% sodium citrate dihydrate, and 2.45% dextrose monohydrate in water for injection, and is used in apheresis and platelet-rich plasma procedures.



The mechanism is straightforward but elegant: citrate acts as an extracorporeal anticoagulant by binding the free calcium in blood, and calcium is a necessary co-factor for several steps in the coagulation cascade. Remove the calcium, and the blood will not clot — but only where the citrate is present. Once the blood returns to the patient, citrate is rapidly metabolised and the anticoagulant effect disappears.



ACD first entered clinical use for apheresis in 1977 and is now preferred over heparin for centrifuge-based systems because it is cheaper, safer, and cleared from the body faster. It is a textbook example of a pharmaceutical where supply-chain quality and sterile-grade sourcing are non-negotiable: these solutions are sterilised by steam, packaged in polyolefin bags, and supplied under USP specification with full traceability.







Application 5: Solubility Enhancement, Co-Crystals, and Co-Amorphous Systems



A more recent area of pharmaceutical development concerns citric acid as a co-former in solid-state formulation strategies for poorly soluble APIs. Citric acid can form co-crystals and co-amorphous systems with APIs, improving their dissolution rate and bioavailability without chemically modifying the drug molecule itself.



Beyond solubility enhancement, citric acid is used in polymer excipients: for example, β-cyclodextrin polymers obtained by crosslinking β-cyclodextrin with citric acid have been developed as multifunctional direct-compression tablet excipients, offering compressibility and flowability suitable for tablet manufacturing.



These advanced applications reflect a broader trend: citric acid is no longer just a pH adjuster. In modern formulation science, it is increasingly exploited as a functional polymer building block and solid-state modifier.







Application 6: Taste Masking in Paediatric and Oral Liquid Formulations



Citric acid plays a discrete but important role in improving patient experience with oral liquid and chewable dosage forms. Bitter APIs — particularly many antibiotics and antivirals — are often unpalatable to the point that paediatric patients refuse them, compromising treatment compliance. Citric acid's tart flavour profile masks bitterness effectively, and the effect is enhanced when combined with sweeteners and flavouring agents.



In oral suspensions, solutions, and elixirs, citric acid's dual role as pH adjuster and taste modifier allows formulators to achieve both chemical stability and patient acceptability in a single ingredient — a particularly useful combination in paediatric formulation development.







Grades and Regulatory Requirements



For pharmaceutical use, only USP or EP pharmacopoeial-grade citric acid is acceptable. Key regulatory considerations include:




Compliance with the citric acid monograph in the relevant pharmacopoeia (USP, EP, JP).



Elemental impurities control per ICH Q3D.



Nitrosamine risk assessments, which have become a standard supplier expectation.



IPEC-GMP or pharmaceutical-grade GMP manufacturing standards for excipient supply.



Full traceability documentation: Certificate of Analysis (CoA), Safety Data Sheet (SDS), and in many cases a Drug Master File (DMF) reference to support regulatory submissions.



Choice between monohydrate and anhydrous forms, selected based on the process requirements (anhydrous for effervescent systems and dry blends; monohydrate for most liquid applications).




For a broader overview of excipient sourcing, documentation, and the role of specialty distributors in pharmaceutical supply chains, see our article on Active Pharmaceutical Ingredients and Excipients: The Distributor's Role.







Formulation Challenges to Watch



A few practical points that recur in pharmaceutical development:




Sucrose inversion in solid-state or lyophilised formulations — citric acid can protonate sucrose even in the solid state, producing invert sugar fragments that may react with other formulation components.



Moisture sensitivity in effervescent systems — the monohydrate form introduces enough water to trigger premature reaction with bicarbonate. Anhydrous is non-negotiable in these formulations.



Incompatibility with alkali-sensitive APIs — the acidic pH that citric acid establishes may destabilise APIs that require neutral or alkaline conditions.



Citrate toxicity in blood products — although this is a clinical rather than formulation concern, it is a documented reality of ACD-based apheresis: citrate reactions may occur with infusion and return of citrate-anticoagulated blood, with symptoms ranging from paraesthesia to hypotension.




Citric Acid Monohydrate vs Anhydrous — Frequently Asked Questions



What is the difference between citric acid monohydrate and anhydrous citric acid?



Both are the same molecule (C₆H₈O₇) but differ in water content. Anhydrous citric acid contains no water molecules in its crystalline structure, while the monohydrate form incorporates one water molecule per citric acid molecule (C₆H₈O₇·H₂O), giving it a molecular weight of 210.14 g/mol versus 192.12 g/mol for the anhydrous form and a water content of approximately 8.6%.



Which form is preferred for effervescent tablets and dry pharmaceutical formulations?



Anhydrous citric acid is the standard choice for effervescent tablets, dry blends, and solid dosage forms. The monohydrate formintroduces moisture that can trigger premature reaction with sodium bicarbonate during manufacturing or storage, compromising tabletintegrity and shelf life.



Is citric acid monohydrate suitable for liquid pharmaceutical formulations?



Yes. For oral syrups, liquid medications, and solutions, both forms are suitable — the water content of the monohydrate is not adrawback in aqueous systems. Monohydrate also tends to dissolve slightly faster initially, which can be an advantage in liquidprocessing. Final solubility in water is equivalent for both forms (approximately 59.2% at 20°C).



Which form is more stable during storage?



Monohydrate is generally more stable in humid environments. Anhydrous citric acid is hygroscopic — it actively absorbs moisture from theair — which makes controlled storage conditions essential when using the anhydrous form in solid formulations.



At what temperature does citric acid monohydrate convert to the anhydrous form?



36.6°C is the transition temperature in the aqueous system. Above it, the anhydrous form is the thermodynamically stable phase in solution, which matters for crystallisation and for any process with a heated aqueous stage.



It is not a solid-state dehydration threshold. Dry monohydrate does not lose its water of crystallisation simply by being stored at 40°C; solid-state dehydration requires substantially higher temperatures. Ordinary warm-climate storage therefore does not convert monohydrate to anhydrous, though the anhydrous form's hygroscopicity still makes humidity control the more important storage variable for solid formulations.



Citric acid earns its place in a pharmaceutical formulation by doing several jobs at once: holding pH, chelating trace metals, generating gas, masking bitterness. That versatility is also what makes it easy to specify carelessly. The form matters, the grade matters, and the interactions with sucrose, with bicarbonate and with alkali-sensitive actives all need to be designed for rather than discovered during stability testing.


USP and EP grade citric acid with CoA, DMF reference and full traceability documentation.

Pharmaceutical excipients

Citric Acid in Pharmaceutical Formulations: Functions, Applications, and Formulation Considerations


TL;DR




A specialty chemicals distributor is a technical intermediary between chemical manufacturers and industrial end-users, not a simple reseller.



Chemical distribution sits between manufacturers and end-use industries, handling sourcing, storage, blending, packaging, logistics, and regulatory compliance.



In Europe, the market was valued at USD 101.91 billion in 2024, growing at a CAGR of 6.44% through 2034.



A specialty distributor's value comes down to six things: access to global supply, regulatory compliance, technical expertise, supply chain resilience, formulation support, and market intelligence. 






What Is a Specialty Chemical?



Before understanding what a distributor does, it helps to understand what they distribute.



Specialty chemicals are sold on the basis of their performance or function, not their composition. They can be single-chemical entities or formulations whose composition directly shapes how a customer's product performs and processes. Unlike commodity chemicals, specialty chemicals are high-value, tailored products designed for specific applications — pharmaceutical excipients, cosmetic actives, rubber processing agents, food additives.



And that specificity is exactly what makes distribution both complex and worth doing well.



What Does a Specialty Chemicals Distributor Actually Do?



A specialty chemical distributor is a third-party intermediary connecting chemical manufacturers with end-users, supplying high-value, application-specific chemicals.



That said, the job goes well beyond moving product. What separates the better distributors today is a broader service offering: technical support, regulatory assistance, custom formulation, and digital tools that simplify procurement and inventory management.



Why Specialty Distributors Are Not Commodity Brokers



In practice, the common assumption is that distributors simply "move boxes." In specialty chemicals, that's wrong.



Manufacturers increasingly treat distributors as part of their go-to-market structure. In competitive markets, the distributor channel is often the most practical way to reach smaller customers or move into new geographies. Distributors take on what manufacturers can't or don't want to handle directly: technical support, formulation work, proprietary compounds, laboratory access, packaging, labeling, and regulatory documentation.



In short, for B2B formulators the distributor is often the first technical contact — before any product has been selected.



The Regulatory Dimension: A Critical Differentiator



In Europe, regulatory complexity is one of the main reasons manufacturers use specialty distributors rather than selling direct.



To put that in perspective: according to Eurostat, over 170,000 chemical substances are registered under REACH, with nearly 4,500 classified as substances of very high concern. Distributors handle compliance with local rules on substance registration, labelling, packaging, customs, and import/export.



In regulated sectors such as pharmaceuticals, food, and cosmetics, this compliance layer is not optional. A distributor operating under GMP and GDP frameworks provides the traceability and documentation that regulators require at every step of the supply chain.



Relevant reading: Active Pharmaceutical Ingredients and Excipients: The Distributor's Role — how a specialty distributor manages GMP/GDP compliance for pharma raw materials.



Supply Chain Resilience: Why It Matters More Than Ever



The EU imported 38% of its key organic chemical intermediates from outside the bloc in 2023. That number matters when a supply disruption hits.



This dependency makes distributor relationships a strategic asset, not just a procurement decision.



Beyond the geopolitical angle, the market is shaped by growing demand for customized solutions, tighter regulatory requirements, and the need for reliable supply continuity.



That’s why a well-positioned specialty distributor keeps multi-source supplier networks, buffer stock, and contingency sourcing in place — which limits exposure to geopolitical disruptions, raw material shortages, and logistics problems.



Relevant reading: Supply Chain Resilience in the Pharmaceutical Industry — how distributor partnerships reduce sourcing risk in regulated supply chains.



Which Industries Rely Most on Specialty Distributors?



Chemical distributors serve a wide range of sectors — automotive, construction, pharmaceuticals, agriculture, electronics, among others. But some have particularly deep dependencies.



In practice, the sectors that rely most on specialty distributors are those where:




Regulatory requirements are strict (pharma, food, cosmetics)



Formulation precision is critical (rubber, coatings, adhesives)



Ingredient volumes are mid-range — too large for direct lab sourcing, too small for manufacturer minimums



Product portfolios change frequently (nutraceuticals, personal care)




Of these, pharmaceuticals account for roughly 17% of the chemical distribution market — a high-value, regulation-intensive segment. Distributors supply active ingredients, intermediates, excipients, solvents, and specialty reagents.



Relevant reading: Pharmaceutical and Nutraceutical Excipients: Market Trends in Europe — key formulation trends driving demand for specialty excipients.



Taken together, chemical distribution has moved well past logistics. It now integrates regulatory compliance, technical coordination, and regional market knowledge — and that's what allows manufacturers and end-users to operate at scale across complex markets.



FAQ



What is the difference between a specialty chemicals distributor and a commodity chemicals distributor?



The distinction is straightforward. A commodity distributor handles bulk, standardized products — solvents, acids — where price and volume are the main variables. A specialty distributor, by contrast, adds technical value: formulation support, regulatory documentation, application expertise, and access to performance-driven ingredients for specific industries.



Why can't manufacturers sell directly to all customers?



Distributors help manufacturers reach customers they couldn't access on their own. Direct sales require local presence, regulatory expertise, and minimum order volumes that many end-users can't meet.



What does "value-added services" mean in chemical distribution?



More than just product supply. Distributors are expanding into formulation support, technical consulting, customized packaging, blending, and compliance assistance. In Europe, these services are increasingly what customers are buying, not just the chemicals.



Is REACH compliance the distributor's responsibility?



Partly, yes — and it’s worth understanding how. Under EU REACH, distributors are classified as "downstream users" or "importers" depending on their position in the supply chain. They are responsible for accurate Safety Data Sheets, proper substance registration, and maintaining downstream communication. This is a core function of any compliant specialty distributor.



How does a specialty distributor support supply chain resilience?



Primarily by keeping multi-supplier relationships, buffer stock, and contingency sourcing plans in place. In volatile markets, that risk management function is often more valuable than the product itself.



What industries benefit most from specialty chemical distribution?



Pharmaceuticals, cosmetics, food &amp; beverage, rubber, coatings, adhesives, nutraceuticals, and animal nutrition — any sector where ingredient performance, regulatory compliance, and formulation precision are non-negotiable.


What is a specialty chemicals distributor and why does it matter?


TL;DR




Carbomer (Carbopol) is the most widely used rheology modifier in cosmetics — but regulatory pressure and clean-label demand are pushing formulators to explore alternatives.



No single drop-in replacement exists. The right alternative depends on your target texture, pH range, electrolyte tolerance, and sustainability claims.



Four main families are gaining ground: natural gums (xanthan, sclerotium), cellulose derivatives (HPMC, HEC), polyacrylate crosspolymers, and clay-based minerals.



EU Regulation (EU) 2023/2055 on microplastics introduces phase-out timelines for certain synthetic polymers in cosmetics — rinse-off products by 2027, leave-on by 2029.








What Is Carbomer — and Why Are Formulators Reconsidering It?



Carbomer is a synthetic polymer of crosslinked polyacrylic acid. When dispersed in water and neutralized (typically with NaOH or triethanolamine), it forms a three-dimensional network that delivers high viscosity, excellent clarity, and shear-thinning behaviour at very low use levels — typically 0.1–0.5%.



It is used in face gels, serums, moisturizers, hand sanitizers, hair gels, and sunscreens. The INCI name "Carbomer" covers a family of grades (Carbopol 940, 980, Ultrez 10, Ultrez 21, etc.), each with distinct rheological profiles.



Three converging pressures are driving reformulation:



1. Microplastics regulation. Commission Regulation (EU) 2023/2055, which entered into force on 17 October 2023, introduces a phased restriction on synthetic polymer microparticles intentionally added to products. For cosmetics, the key deadlines are: rinse-off products by 17 October 2027, leave-on products (creams, gels, serums) by 17 October 2029. Whether carbomer falls within scope depends on particle size and solubility — formulators should verify with their regulatory team. The ECHA microplastics hub provides the latest guidance.



2. Clean-label and consumer perception. Consumers and health practitioners increasingly scrutinize ingredient lists. Polyacrylic acid polymers face reputational risk in natural and Ecocert-certified product lines, even when compliant.



3. Electrolyte sensitivity. Carbomers are highly sensitive to electrolytes — salts, cationic actives, and high-mineral water can collapse the polymer network and dramatically reduce viscosity. This is a real formulation constraint in high-active or multi-functional products.







The Four Main Families of Carbomer Alternatives



1. Natural Gums



The most widely discussed alternatives. They are biodegradable, consumer-friendly, and compatible with natural and organic certifications (Ecocert, COSMOS).




Xanthan gum is the most commonly used natural-based thickener. It offers excellent salt tolerance, good suspending properties, and stability across a wide pH and temperature range. However, it requires a significantly higher use level than carbomer to reach equivalent viscosity — typically 1–2% vs. 0.1–0.5% for carbomer — and produces a longer, more stringy flow that some consumers find less elegant.



Sclerotium gum (produced by fermentation of Sclerotium rolfsii) delivers a smooth, short-flow texture closer to carbomer, with good transparency and Ecocert compatibility. It is increasingly used in premium natural formulations.



Gellan gum (with sodium salts) produces a strongly shear-thinning gel with short flow — one of the closest rheological profiles to carbomer among natural alternatives.



Tara gum and guar gum are better suited to opaque, high-viscosity systems (creams, masks) where transparency is not required.





Formulator's note: Natural gums can show batch-to-batch variability in colour and viscosity. Shelf stability of emulsions formulated with natural-only systems can be a challenge — major brands typically require 3+ years of stability.




2. Cellulose Derivatives



Semi-synthetic, derived from plant cellulose. They offer a middle ground between natural origin and technical performance.



Hydroxyethyl cellulose (HEC) is a non-ionic thickener, compatible with electrolytes and cationic actives — a key advantage over carbomer. It is a standard choice for shampoos, conditioners, and cleansing gels. Hydroxypropyl methylcellulose (HPMC) forms films well and works in both cosmetic and pharmaceutical topical products. Unlike many gelling agents, it is pH-independent and gels on heating rather than cooling. Carboxymethyl cellulose (CMC / cellulose gum) is anionic, compatible with transparent systems, and a reliable suspending agent all the while being also Ecocert-approved.




Other cellulose derivatives have lower electrolyte resistance than HEC, though still higher than carbomer.




3. Polyacrylate Crosspolymers (Next-Generation Acrylics)



For formulators who need carbomer-like performance without the limitations, next-generation acrylate copolymers offer a compelling option.




Acrylates/C10-30 Alkyl Acrylate Crosspolymer (e.g., Pemulen, Ultrez 21) is an associative thickener that provides thickening in high-electrolyte media, acts synergistically with surfactants, and facilitates dispersion of fillers — addressing carbomer's main weakness.



Polyacrylate Crosspolymer-6 (e.g., SEPIMAX Zen by Seppic) is a pre-neutralized, cold-process thickener with outstanding electrolyte resistance. A 2% dispersion with 2% salt reaches ~45,000 cps. It requires no pH adjustment and you can add it at the end of the process.



Sodium carbomer (pre-neutralized) delivers a lighter, smoother texture than conventional carbomer, with greater process flexibility — no neutralization step required.





These next-generation polyacrylates are not natural, but they address the electrolyte sensitivity and process complexity issues of carbomer. Their regulatory status under (EU) 2023/2055 should be verified on a case-by-case basis.




4. Clay and Mineral-Based Thickeners



On the one hand, magnesium aluminum silicate (e.g., Veegum) is a natural mineral thickener with strong synergy with anionic polymers (xanthan gum, CMC) and provides high yield value and good suspension properties, particularly in rinse-off and colour cosmetic systems. 



On the other hand, Laponite (synthetic hectorite clay) delivers excellent transparency and thixotropy in water-based gels. It is compatible with electrolytes and provides a unique "gel-in-gel" texture.



The Regulatory Context: EU Microplastics Restriction



A Commission Regulation (EU) 2023/2055 restricts synthetic polymer microparticles (SPM) intentionally added to products. However, it is not a blanket ban on all synthetic polymers as applicability depends on particle size, solubility, and biodegradability criteria defined in Annex XVII, Entry 78 of REACH. 



How to Choose the Right Alternative



Unfortunately, there is no universal drop-in for carbomer. The selection depends on five parameters:




Target texture. Gellan gum and polyacrylate crosspolymers give short, firm gels. For something longer and more fluid, xanthan gum or HEC is the better fit.



Electrolyte content. High-salt and high-active formulas call for HEC, xanthan gum, or next-generation acrylatecrosspolymers. Conventional carbomer will not hold up.



pH range. Carbomer needs to be activated at pH 5-10, so it is off the table for acidic formulas. HEC and xanthangum have no such constraint, which is why they tend to dominate in the pH 3-5 range.



Sustainability claims. COSMOS/Ecocert certification narrows the options to xanthan gum, sclerotium gum, cellulosegum, and magnesium aluminum silicate. For clean-label positioning without formal certification, cellulose derivativesor bio-attributed acrylics are reasonable alternatives.



Process constraints. Cold process? SEPIMAX Zen (Polyacrylate Crosspolymer-6), pre-neutralized sodium carbomer, andxanthan gum all work without heat. HPMC is the exception: it requires heat to hydrate properly.




For a broader overview of rheology modifier selection across industries, see our article on rheology modifiers in cosmetics and coatings.



Natural Hydrocolloids: A Growing Formulation Tool



Natural gums belong to the broader family of hydrocolloids which are hydrophilic biopolymers capable of absorbing water and forming viscous solutions, pseudogels, or true gels. 



Beyond thickening, they help stabilize emulsions, suspend particles, and create textures that meet modern expectations for naturality and sensory performance.



The demand for natural hydrocolloids continues to grow as brands seek clean-label, sensory-rich, and environmentally responsible alternatives. For a deeper dive into how to formulate with them, see our article on natural hydrocolloids and innovative textures in cosmetics.



What Is NOT Changing




Carbomer remains approved under the EU Cosmetics Regulation (EC) No 1223/2009. There is no current ban on its use in cosmetics.



The microplastics restriction is phased. Transitional periods give formulators time to reformulate.



Performance remains the primary criterion. As noted at In-Cosmetics Global 2025, biobased alternatives have struggled with long-term stability — major brands require 3+ years of shelf life, which remains a challenge for purely natural systems.



Blending strategies are valid. Many formulators combine two or more thickeners (e.g., xanthan + HEC, or sclerotium + magnesium aluminum silicate) to achieve the target rheological profile while meeting sustainability claims.




Use levels are indicative and vary by grade. Microplastics scope must be assessed per REACH Annex XVII, Entry 78.







FAQ



What is carbomer used for in cosmetics?



Carbomer is a synthetic polymer of crosslinked polyacrylic acid used as a rheology modifier — it thickens, gels, stabilizes emulsions, and suspends particles. It is found in face gels, serums, moisturizers, hand sanitizers, and hair gels, typically at 0.1–0.5%.



Is carbomer banned in the EU?



No. Carbomer is not banned under the EU Cosmetics Regulation (EC) No 1223/2009. However, Commission Regulation (EU) 2023/2055 on microplastics introduces phased restrictions on certain synthetic polymer microparticles. Whether specific carbomer grades fall within scope depends on their physicochemical properties — formulators should assess this on a case-by-case basis with regulatory support.



What is the best natural alternative to carbomer?



There is no single best alternative. Xanthan gum is the most widely used natural thickener — it offers excellent electrolyte tolerance and Ecocert compatibility, but requires higher use levels and produces a longer flow than carbomer. Sclerotium gum delivers a smoother, shorter texture closer to carbomer. The right choice depends on your target texture, pH, and formulation constraints.



Can I replace carbomer 1:1 with xanthan gum?



No. Natural thickeners cannot be used as direct weight-for-weight replacements. To achieve the same viscosity as 0.2% carbomer, approximately 2% xanthan gum is typically required. Texture and skin feel will also differ — natural gums produce a longer, more stringy flow compared to carbomer's short, firm gel.



Are polyacrylate crosspolymers subject to the EU microplastics restriction?



It depends on the specific polymer, its particle size, solubility, and biodegradability. The restriction targets synthetic polymer microparticles meeting specific criteria defined in Annex XVII, Entry 78 of REACH. Water-soluble polymers are excluded. Formulators should verify each ingredient against the ECHA guidance before drawing conclusions.



How does electrolyte sensitivity affect carbomer performance?



Carbomers build viscosity through electrostatic repulsion between carboxylate groups. In the presence of electrolytes (salts, cationic actives), this repulsion is reduced — the polymer chains contract, viscosity drops, and the gel can collapse. This is why high-salt or high-active formulas typically require electrolyte-tolerant alternatives such as HEC, xanthan gum, or next-generation acrylate crosspolymers.


Natural gums, cellulose derivatives and acrylate crosspolymers, with technical documentation.

Cosmetic rheology modifiers

Carbomer Alternatives: Natural and Synthetic Options for Cosmetic Formulators


Five Structural Shifts Reshaping the European Market



The European pharmaceutical and nutraceutical markets are navigating a period of significant structural change.



Regulatory tightening, evolving patient expectations, and the post-pandemic acceleration of self-care are collectively reshaping what it means to bring a finished dosage form to market. At the core of this transformation lies an often-underestimated variable: excipient strategy.



1. The Patient-Centric Turn



Consumers are no longer passive recipients of pharmaceutical products.



Across Europe, an ageing population combined with growing health literacy is pushing manufacturers to prioritize tolerability, ease of swallowing, and taste masking alongside efficacy. Older people are the fastest growing population group in Europe and are the main users of medicines — a dynamic that EMA has formally integrated into its medicines development framework.



This trend is particularly visible in the OTC and nutraceutical segments, where purchase decisions are made by end-users without medical intermediaries. According to Mordor Intelligence, the European OTC drugs market is projected to reach USD 46.44 billion by 2031 — with gummies and dissolvable films growing at 10.83% annually as manufacturers respond to pill-fatigued consumers.



The practical implication for formulators is clear: excipients are no longer purely functional infrastructure. Their sensory properties, their compatibility with clean-label positioning, and their contribution to product elegance have become genuine differentiators in a competitive shelf environment. As ONdrugDelivery notes, leveraging specialised excipients is now the primary lever for developing more patient-centric formulations that improve outcomes for older patients.



2. Clean-Label Pressure Reaches Solid Dosage



What began as a trend in food and cosmetics has steadily migrated into pharmaceutical and nutraceutical formulation.



Consumers — and increasingly, health practitioners — scrutinize ingredient lists. Excipients derived from synthetic or poorly-understood origins face growing reputational risk, even when regulatory compliance is assured. German consumers value product quality and often favour herbal or natural alternatives, which has encouraged companies to invest in clean-label and plant-based formulations.



This has accelerated interest in excipients with well-established origins, transparent safety profiles, and natural or semi-natural derivation. Starches, polyols, and plant-derived functional ingredients benefit from this dynamic, provided they can deliver the technical performance that complex formulations require.



3. The Rise of Direct Compression and Continuous Manufacturing



Process efficiency is exerting its own pressure on excipient selection.



As manufacturers across Europe migrate toward direct compression (DC) and continuous manufacturing platforms — driven by both cost optimization and regulatory encouragement — the demand for excipients offering outstanding flowability, compressibility, and batch-to-batch consistency has intensified sharply. Both the FDA and EMA actively encourage continuous manufacturing as it aligns with the Quality by Design (QbD) paradigm. ICH Q13 — adopted by EMA in July 2023 — now provides the harmonized regulatory framework for its implementation across Europe.



Traditional wet granulation workflows remain relevant, but the economics of DC are compelling. Formulators consequently need excipients that perform reliably at high throughput, with minimal sensitivity to environmental variables such as humidity — a meaningful consideration for production facilities across Northern Europe and the British Isles.



4. Supply Chain Resilience as a Strategic Imperative



The disruptions of recent years exposed significant vulnerabilities in pharmaceutical ingredient supply chains.



European manufacturers, previously reliant on concentrated sourcing from a handful of global regions, have since prioritized supplier diversification, regional availability, and long-term partnership stability. As Safic-Alcan's analysis of supply chain resilience in the pharmaceutical industry highlights, selecting at least two or three sources of key ingredients — and relying on distributors with direct local presence in key sourcing markets — is now a strategic necessity, not a contingency measure.



For excipient procurement teams, this translates into a preference for distributors capable of covering multiple European markets under a single partnership framework — reducing administrative overhead while guaranteeing consistent quality standards and regulatory documentation across jurisdictions.



5. Nutraceuticals: A Growing Appetite for Pharmaceutical-Grade Standards



The boundary between nutraceuticals and pharmaceuticals continues to blur.



As supplement manufacturers position their products in therapeutic adjacencies — digestive health, cognition, immunity — they increasingly adopt pharmaceutical-grade formulation standards, including the use of excipients validated for drug applications. As explored in our article on evidence-based nutraceuticals, for premium or science-driven products, investing in ingredients supported by in-vivo and clinical research has become essential to secure regulatory compliance and market trust.



This convergence creates new sourcing requirements: excipients that are technically suited to both regulated pharmaceutical manufacturing and the faster, more agile development cycles typical of the nutraceutical industry. Multi-functional excipients capable of serving as fillers, binders, and flow agents simultaneously are particularly valued in this context.




Five Structural Shifts Reshaping the European Market


TL;DR



Three major changes affect Annex V (permitted preservatives) in 2026:




1 May 2026 — Commission Regulation (EU) 2026/78 applies: entry 7 of Annex V is replaced to add Sodium o-Phenylphenate alongside o-Phenylphenol, with a combined concentration limit and three new conditions of use. Fifteen CMR substances are added to Annex II. No transitional period.



31 July 2026 — 31 July 2026 — Deadline for placing on the market products complying with the expanded fragrance allergen labelling list under Regulation (EU) 2023/1545. Products already on the market may be made available until 31 July 2028.






What&nbsp;Is Annex V of the EU Cosmetics&nbsp;Regulation?&nbsp;



Annex V of Regulation (EC) No 1223/2009 is the list of permitted preservatives in cosmetic products sold within the European Union and EEA.



For each listed substance, Annex V specifies:




Name and INCI designation — chemical name and CAS/EC number



Maximum concentration — per product type (rinse-off vs. leave-on)



Scope restrictions — product categories, application routes, age groups



Mandatory label warnings — where required for consumer safety




Preservatives not listed in Annex V cannot be used as such in EU cosmetic products. Annex V is updated regularly as the Scientific Committee on Consumer Safety (SCCS) issues new opinions and as CMR classifications under the CLP Regulation are updated.



The Key Driver in&nbsp;2026:&nbsp;CMR Reclassifications Under the CLP&nbsp;Regulation&nbsp;



Most 2026 changes to Annex V are driven by a single upstream event: Commission Delegated Regulation (EU) 2024/2564 — the 21st Adaptation to Technical Progress (ATP) of the CLP Regulation — which updated the harmonised classification of several substances as CMR (carcinogenic, mutagenic, or reprotoxic).



Under Article 15 of Regulation (EC) No 1223/2009, CMR substances of category 1A, 1B, or 2 are prohibited in cosmetics by default, unless the SCCS has assessed them as safe under specific conditions of use.



This mechanism directly triggered Commission Regulation (EU) 2026/78, published on 13 January 2026, which amends Annexes II, III, IV, and V of the Cosmetics Regulation. Application date: 1 May 2026. No transitional period.



Understanding the CLP-to-Cosmetics pipeline is essential for anticipating future restrictions. Safic-Alcan's regulatory team monitors these classifications upstream — for more on how REACH and SVHC classifications interact with cosmetic compliance obligations, see our dedicated article.



Annex V Changes Effective 1 May 2026&nbsp;



This is the most significant Annex V change in 2026.



Background: o-Phenylphenol (CAS 90-43-7, INCI: o-Phenylphenol) has been listed in Annex V, entry 7, as a permitted preservative for rinse-off and leave-on products. It was reclassified as a CMR category 2 carcinogen by Delegated Regulation (EU) 2024/2564.SCCS assessment: The SCCS issued its opinion on 25 October 2024 concluding that both o-Phenylphenol and its sodium salt (Sodium o-Phenylphenate, CAS 132-27-4) can be considered safe under specific conditions.



What changes in entry 7 from 1 May 2026:







Phenoxyethanol: 



Key formulation&nbsp;implications:&nbsp;




Products using o-Phenylphenol alone: update CPSR and labelling to reflect new warning and use restrictions.



Products using both substances: verify combined concentration compliance.



Spray or aerosol formats: assess inhalation exposure risk — reformulation may be required.



Oral care products (mouthwash, toothpaste): these preservatives are now prohibited.




New CMR Substance Bans&nbsp;Affecting&nbsp;Annex V&nbsp;



Regulation (EU) 2026/78 also adds several CMR substances to Annex II (prohibited substances). Among those relevant to preservation systems:




Trimethyl borate (CAS 121-43-7) — prohibited from 1 May 2026, no adaptation period.



N,N'-methylenediacrylamide (CAS 110-26-9) — prohibited from 1 May 2026.




These bans apply regardless of concentration. Any product containing these substances must be withdrawn from the EU market by 1 May 2026. There is no sell-through period.



Annex V&nbsp;Preamble&nbsp;Change:&nbsp;Formaldehyde-Releasing&nbsp;Preservatives&nbsp;



This change does not originate from Regulation (EU) 2026/78 — it stems from Commission Regulation (EU) 2022/1181, which amended the preamble of Annex V.



What changes: The threshold triggering the mandatory formaldehyde warning is reduced from 0.05% (500 ppm) to 0.001% (10 ppm). New mandatory warning text (from July, 31 2026): "releases formaldehyde" — required on all finished products where the total concentration of formaldehyde released exceeds 0.001%, regardless of whether one or multiple formaldehyde-releasing substances are present.



Commonly affected preservatives in Annex V:







Why the threshold was lowered: The SCCS concluded that the previous 0.05% threshold was insufficient to protect consumers already sensitised to formaldehyde from developing contact dermatitis. This is a consumer safety-driven amendment, not a CMR reclassification.Sell-through deadline: Products compliant with the old regulation (pre-July 2022) could be placed on the market until 31 July 2024, and made available until 31 July 2026. After this date, full compliance is mandatory.



For formulators using these preservatives, the practical question is binary: either add the new warning, or reformulate to bring released formaldehyde below 10 ppm. Safic-Alcan's cosmetics team can support the identification of alternative preservation systems — our article on cosmetic microbiology and preservation covers the technical principles and available solutions.



What&nbsp;Is Not&nbsp;Changing&nbsp;in Annex V in 2026&nbsp;



To avoid confusion, it is worth clarifying what is not affected by 2026 Annex V changes:




Parabens — no new restrictions in 2026. Existing limits remain.



Phenoxyethanol — no change in 2026. Still permitted at 1% maximum.



Benzyl alcohol — no change in 2026.



Chlorphenesin — no change in 2026.




These substances remain under ongoing SCCS review as part of the broader regulatory programme, but no application deadlines apply in 2026.



What&nbsp;Formulators&nbsp;and&nbsp;Regulatory&nbsp;Teams&nbsp;Should&nbsp;Do&nbsp;Now&nbsp;



1. Audit&nbsp;your&nbsp;preservation&nbsp;systems&nbsp;



Identify&nbsp;all&nbsp;products&nbsp;using&nbsp;o-Phenylphenol, Sodium o-Phenylphenate,&nbsp;formaldehyde-releasing&nbsp;preservatives, or&nbsp;any&nbsp;substance&nbsp;newly&nbsp;added&nbsp;to Annex II&nbsp;under&nbsp;EU 2026/78. Cross-reference&nbsp;against&nbsp;the&nbsp;updated&nbsp;annexes.&nbsp;



2. Update&nbsp;CPSRs&nbsp;



Any change in formulation, concentration, or use conditions requires an updated Cosmetic Product Safety Report. Ensure your safety assessor is aware of the new CMR classifications and SCCS opinions.



3.&nbsp;Revise&nbsp;labelling&nbsp;




Add&nbsp;"Avoid&nbsp;contact&nbsp;with&nbsp;eyes" for&nbsp;products&nbsp;containing&nbsp;o-Phenylphenol&nbsp;or Sodium o-Phenylphenate.&nbsp;





Add&nbsp;"releases&nbsp;formaldehyde" warning&nbsp;where&nbsp;applicable (threshold: 0.001%).&nbsp;





Verify&nbsp;INCI nomenclature&nbsp;against&nbsp;the&nbsp;updated&nbsp;glossary&nbsp;(mandatory&nbsp;from&nbsp;30 July 2026).&nbsp;




4.&nbsp;Assess&nbsp;spray and&nbsp;aerosol&nbsp;formats&nbsp;specifically&nbsp;



The prohibition of o-Phenylphenol&nbsp;in applications&nbsp;with&nbsp;inhalation&nbsp;exposure&nbsp;is&nbsp;new. Spray,&nbsp;mist, and&nbsp;aerosol&nbsp;formats&nbsp;using&nbsp;this&nbsp;preservative&nbsp;require&nbsp;immediate&nbsp;reformulation&nbsp;assessment.&nbsp;



5. Clear non-compliant stock&nbsp;



For substances&nbsp;banned&nbsp;under&nbsp;EU 2026/78&nbsp;with&nbsp;no&nbsp;transitional&nbsp;period:&nbsp;products&nbsp;must not&nbsp;be&nbsp;placed&nbsp;on the EU&nbsp;market&nbsp;after&nbsp;1 May 2026. There&nbsp;is&nbsp;no&nbsp;sell-through&nbsp;window.&nbsp;



FAQ



What is Annex V of the EU Cosmetics Regulation?



Annex V of Regulation (EC) No 1223/2009 is the list of preservatives permitted for use in cosmetic products sold in the EU and EEA. It specifies maximum concentrations, product type restrictions, and mandatory label warnings for each listed substance.



What is the most important Annex V change in 2026?



The amendment of entry 7 under Commission Regulation (EU) 2026/78, applicable from 1 May 2026. It adds Sodium o-Phenylphenate to the permitted preservatives list alongside o-Phenylphenol, introduces new concentration limits for combined use, prohibits use in products with inhalation exposure and in oral products, and requires the warning "Avoid contact with eyes".



Why are these changes happening?



Most 2026 changes are driven by updated CMR classifications under Commission Delegated Regulation (EU) 2024/2564 (21st ATP to the CLP Regulation). When a substance is reclassified as CMR, its use in cosmetics is automatically reviewed under Article 15 of the Cosmetics Regulation. The SCCS then assesses whether a safe use condition exists.



Does Regulation (EU) 2026/78 have a transitional period?



No. The regulation applies from 1 May 2026 with no adaptation period for the CMR substance bans. Products containing newly prohibited substances must be withdrawn from the EU market by that date.



Which formaldehyde-releasing preservatives are commonly used in cosmetics?



The most common are DMDM Hydantoin, Imidazolidinyl Urea, Diazolidinyl Urea, and Quaternium-15. All are listed in Annex V and are permitted, but products containing them must now carry the "releases formaldehyde" warning if released formaldehyde exceeds 0.001% (10 ppm) in the finished product — a deadline that applies from July, 31st 2026.



Where can I find the official updated text of Annex V?



The consolidated version of Regulation (EC) No 1223/2009, including all annexes, is available on EUR-Lex. Commission Regulation (EU) 2026/78 is published in the Official Journal of the EU.



Is Safic-Alcan able to support reformulation in response to these changes?



Yes. Safic-Alcan's cosmetics team provides regulatory monitoring, ingredient sourcing, and formulation support across preservation systems. Contact our specialists for guidance on compliant alternatives and updated ingredient portfolios.



What is the maximum concentration of phenoxyethanol allowed under EU Annex V?



1.0% in the finished product, covering total phenoxyethanol from all sources. This limit is long-standing and was not changed in 2026. Regulation (EU) 2026/78 does not amend the phenoxyethanol entry. Use in products for children under three in the nappy area is prohibited, following SCCS opinion SCCS/1575/16.






EU Cosmetics Regulation Annex V — What's Changing in 2026

It looks like this molecule has broken down... but we’ll reconstitute it in no time.

The page you are looking for may have evaporated, been neutralized, or simply hasn’t been synthesized yet. We’ll help you find the right compound.

Formula not found!

Page not found title

Page not found

Twitter title

To view products available in a different region, please select your location below.

You are being redirected to the Safic-Alcan {country} catalog.

Safic Alcan - Home

You’ll be redirected to our main careers page to see the full details and apply.

View this job offer on our corporate website

To view the products available in your region, please select your location below.

Welcome to 
the Safic Alcan website!

About

Certifications & Documents

Countries covered

Markets covered

We couldn’t find any results matching your search. Explore our full range of specialty chemicals and solutions.

We couldn’t find any results matching your search.

No results found

Safic-Alcan, distributor of {supplier} {countryIn}. Explore the {supplier} product range and applications. Request a TDS, a sample or a quote.

Insights from the Industry